Recombinant humanized (from mouse) antibody Fab fragment expressed in CHO binding to human CFD. Lampalizumab is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
DrugMonitor™ Anti-Lampalizumab Antibody (VS-1224-YC636)Lampalizumab has been studied in clinical trials for treating geographic atrophy. The DrugMonitor™ Anti-Lampalizumab Antibody (VS-1224-YC636) is an anti-drug antibody (ADA) against Lampalizumab. This drug-based antibody is raised in mice immunized with the Lampalizumab. The anti-Lampalizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Lampalizumab in samples.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
PNBL-034 | Recombinant Anti-CHRM2 VHH Single Domain Antibody (PNBL-034) | FACS | Llama VHH |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-754, RRID: AB_3112001)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.